Introduction

The importance of transmembrane interactions
Integral membrane proteins are anchored in cell membranes by transmembrane domains that engage in hydrophobic interactions with the lipid bilayer. In some cases, the assembly of protein complexes and the folding of proteins that cross the membrane multiple times is mediated by interactions between transmembrane domains. It is thought that the great majority of transmembrane segments traverse the lipid bilayer as a-helices. Engelman and colleagues proposed a two-step model for the oligomerization of transmembrane helices, in which hydrophobic a-helical segments first insert across the membrane bilayer, followed by specific sideby-side interactions between these helices to fold multipass proteins and to assemble oligomeric complexes (Popot and Engelman, 1990) . The amino-acid sequence of the membrane-spanning segments determines their ability to homo-and hetero-dimerize with high specificity (e.g., Lemmon et al., 1992a; Brosig and Langosch, 1998; Call et al., 2002; Chen et al., 2002; DeGrado et al., 2003) . Most amino acids in transmembrane domains are hydrophobic, and specific interhelical interactions can be mediated by van der Waals contacts between these hydrophobic side chains (Lemmon et al., 1992b (Lemmon et al., , 1994 Bowie, 1997; Fleming et al., 1997; Langosch and Heringa, 1998; Gurezka et al., 1999; Eilers et al., 2000; Russ and Engelman, 2000; Adamian and Liang, 2001) . Hydrophilic residues can also contribute strong interactions to the oligomerization of some transmembrane helices through hydrogen bond formation or charge pair interactions (e.g., Manolios et al., 1990; Cosson et al., 1991; Smith et al., 1996; Choma et al., 2000; Zhou et al., 2000; Gratkowski et al., 2001; Senes et al., 2001; Therien et al., 2001; Dawson et al., 2002; Partridge et al., 2002) .
The importance and specificity of transmembrane interactions is highlighted by two examples of viral proteins that transform cells by interacting with the transmembrane domains of cellular growth factor receptors. Strikingly, these viral proteins bear no resemblance to the natural ligands of these receptors. gp55 is a 55 kDa transmembrane glycoprotein encoded by the Friend Erythroleukemia Virus, and it is responsible for the early polyclonal stage of red cell proliferation in virus-induced erythroleukemia. Seminal studies carried out Li et al. (1989) demonstrated that gp55 acts by binding to and activating the erythropoietin receptor (EPOR), a cellular transmembrane protein whose extracellular domain normally binds erythropoietin, a soluble cytokine that stimulates proliferation of erythrocyte precursors. Genetic experiments analyzing gp55 derived from different virus strains revealed that the ability of gp55 to activate the EPOR was determined by the transmembrane domain of the viral protein (Zon et al., 1992; Constantinescu et al., 2003) . Indeed, mutational analysis of gp55 and the EPOR demonstrated that single amino-acid substitutions within the transmembrane domains of these two proteins can determine whether or not they engage in a productive interaction, suggesting that these domains directly contact one another (Constantinescu et al., 1999) . The second example of a viral-transforming protein that activates a cellular receptor by transmembrane interactions is the bovine papillomavirus type 1 (BPV) E5 protein, which transforms cells by activating the cellular platelet-derived growth factor (PDGF) b receptor. However, in contrast to gp55, the E5 protein is comprised almost exclusively of a transmembrane domain, suggesting that it may serve as a modular scaffold for building similar small transmembrane proteins with interesting biological properties.
The transmembrane bovine papillomavirus E5 protein binds and activates the PDGF b receptor
The BPV E5 gene encodes a 44 amino-acid protein with a very hydrophobic central segment, interrupted only by a glutamine at position 17 (Figure 1 ). The E5 protein is the major transforming protein of BPV in cultured fibroblasts (DiMaio et al., 1986; Schiller et al., 1986) . In transformed cells, the E5 protein exists as a disulfidelinked type II transmembrane homodimer localized largely to the membranes of the endoplasmic reticulum and Golgi apparatus (Schlegel et al., 1986; Burkhardt et al., 1987 Burkhardt et al., , 1989 Surti et al., 1998) . Transformation requires Gln17, Asp33, and two conserved cysteine residues in the carboxy-terminus that mediate disulfide bond formation, but activity is not impaired by a variety of hydrophobic substitution mutations in the central hydrophobic domain of the E5 protein (Horwitz et al., 1988; Meyer et al., 1994) . The E5 protein induces transformation by activating the PDGF b receptor, a type I transmembrane receptor tyrosine kinase (Petti et al., 1991; Nilson and DiMaio, 1993; Lai et al., 2005) . Each E5 dimer binds to two molecules of the PDGF b receptor, resulting in dimerization of the receptor, tyrosine phosphorylation of each receptor molecule in the complex by the other, and activation of cellular SH2 domain-containing signaling proteins (Goldstein et al., 1992; Petti and DiMaio, 1992; Drummond-Barbosa et al., 1995; Lai et al., 1998 Lai et al., , 2000 Lai et al., , 2005 . PDGF b receptor mutants lacking the extracellular ligand-binding domain still bind the E5 protein and support efficient E5-mediated transformation even though they no longer bind PDGF (Goldstein et al., 1992; Drummond-Barbosa et al., 1995) . Thus, the E5 protein activates the PDGF b receptor by a ligand-independent mechanism. Genetic and pharmacologic experiments indicate that the interaction between the PDGF b receptor and the E5 protein is required for acute mitogenic signaling and cell transformation (Nilson and DiMaio, 1993; Goldstein et al., 1994; Drummond-Barbosa et al., 1995; Riese and DiMaio, 1995; Klein et al., 1998; Lai et al., 2005) .
Complex formation between the E5 protein and the PDGF b receptor is highly specific and depends on transmembrane interactions. The E5 protein does not bind and activate other receptor tyrosine kinases, not even the closely related PDGF a receptor (Goldstein et al., 1994; Petti and DiMaio, 1994; Staebler et al., 1995) . The E5 protein is also not able to activate PDGF b receptor mutants carrying a foreign transmembrane domain (Cohen et al., 1993; Goldstein et al., 1994) , and a number of point mutations in the transmembrane domain of the PDGF b receptor interfere with E5 binding, E5-mediated receptor activation, and cell transformation (Petti et al., 1997; . Finally, a small segment of the receptor consisting largely of the transmembrane domain is sufficient for stable complex formation with the E5 protein . Taken together with the small size of the E5 protein (which is essentially a transmembrane domain), these results indicate that the E5 protein interacts with the transmembrane domain of the PDGF b receptor.
On the basis of genetic experiments and molecular modeling, we proposed that the E5 dimer transits the membrane as a symmetric left-handed coiled-coil in which each E5 monomer contributes Leu10, Ala14, Gln17, Leu21, Leu24, and Phe28 to the E5 homodimer interface Mattoon et al., 2001) . Furthermore, dimerization of the E5 protein is required for stable complex formation with the PDGF b receptor and receptor activation (Horwitz et al., 1988; Meyer et al., 1994; Mattoon et al., 2001) . Finally, because the E5 protein and the PDGF receptor are thought to traverse the membrane in opposite orientations, the transmembrane domains of these two proteins evidently align in an antiparallel orientation. On the basis of these results and extensive biochemical and mutational analysis, we proposed a model in which dimerization of the E5 protein creates binding sites for the transmembrane domains of two molecules of the PDGF b receptor, one on each face of the E5 dimer, resulting in receptor dimerization and activation ( Figure 2 ) . Productive interaction between the E5 protein and the PDGF b receptor requires the integrity of Gln17 and Asp33 in the E5 protein as well as juxtamembrane Lys499 and transmembrane Thr513 in the PDGF b receptor (Horwitz et al., 1988; Meyer et al., 1994; Sparkowski et al., 1994; Nilson et al., 1995; Petti et al., 1997; Klein et al., 1998 Klein et al., , 1999 , suggesting the existence of essential hydrophilic interactions between Gln17 and Thr513 and between Asp33 and Lys499. There also appear to be additional packing contacts between hydrophobic side chains in the transmembrane domains ( ; L Ely and D DiMaio, unpublished). Thus, the high affinity, specific interaction between the E5 protein and the PDGF b receptor appears to involve a variety of interactions along the length of the transmembrane domains. The proposed structure of the E5 protein/PDGF b receptor complex implies that isolated transmembrane domains can insert independently into cellular membranes and undergo specific heteromeric interactions. These results raise the possibility that cells themselves encode small transmembrane proteins that modulate cell function by binding to the transmembrane domains of larger proteins. For example, synthesis of a small protein that interferes with the activity of a growth factor receptor may provide The E5 protein as a modular scaffold to construct novel transmembrane proteins that activate the PDGF b receptor One of the main goals of cell biology and gene therapy is to manipulate the phenotype of cells in a predictable fashion. Since many proteins are regulated by dimerization (Klemm et al., 1998; Weiss and Schlessinger, 1998) , a general method to modulate the dimerization state of cellular proteins would have immense value. An approach to induce dimerization of cellular proteins has been described in which the protein of interest is fused to the protein FKBP12, which binds to the small immuosuppressive compound FK506. Treatment with FK1012, a dimeric version of FK506, results in dimerization of the fusion proteins (Klemm et al., 1998; Yang et al., 1998; Clemons, 1999) . However, this approach cannot be applied to native, endogenous proteins because the target protein must first be genetically fused to FKBP12. The mechanism of E5 action suggests a new approach to specifically manipulate the activity of endogenous proteins, namely to use the E5 protein as a basis to design small transmembrane proteins that can bind to and modulate the activity of various cellular and viral transmembrane proteins.
To test whether the E5 dimer can be used as a modular scaffold from which diverse transmembrane amino acid sequences are displayed, we devised a method to select small proteins with novel transmembrane sequences that specifically activated the PDGF b receptor (Freeman-Cook et al., 2004) . We constructed a library in which 15 transmembrane amino acids of the E5 protein were replaced with random, hydrophobic amino acids (Figure 1) . The glutamine at position 17 and aspartic acid at position 33 were retained, since these residues are important for binding to the PDGF b receptor. The C-terminus of the protein, containing two cysteine residues important for homodimerization, was also retained. Novel transforming proteins were selected from this library based on their ability to induce focus formation in cultured mouse fibroblasts (Figure 3) . Remarkably, even though fully one-third of the E5 protein was randomized, approximately 10% of the library clones induced transformation. The fact that such a high fraction of the library proteins were transformation competent confirmed that the E5 protein was a suitable scaffold, because all of the active proteins were presumably stable, properly folded, and inserted into the membrane, even though they contained random hydrophobic sequences. Inspection of the sequences of the active proteins recovered from transformed cells revealed that many different sequences were able to induce transformation (Figure 4 ). This result is consistent with the construction of a limited number of active E5-like proteins in earlier experiments (Horwitz et al., 1989; Kulke et al., 1992; Meyer et al., 1994) .
All of the transformation-competent proteins from the library formed a stable complex with the endogenous PDGF b receptor, induced its tyrosine phosphorylation, and stimulated PDGF b receptor-mediated signaling in a transient assay (Figure 5) , and the transformed phenotype of cells expressing these proteins Figure 3 Scheme to select and recover randomized transmembrane proteins that transform cells. TM retrovirus library encodes small proteins with randomized hydrophobic domains. Proteins were selected for focus formation in mouse C127 fibroblasts, and active isolates were recovered by PCR from transformed cells and sequenced. Cartoon on far right represents active dimers with random transmembrane domains was reverted by a specific PDGF receptor kinase inhibitor. Furthermore, activation of the PDGF b receptor by the transforming library clones required specific interactions between the library proteins and the transmembrane domain of the PDGF b receptor. Like the E5 protein, the transforming proteins recovered from the library formed dimers, and molecular modeling suggested that they adopted a structure similar to the E5 protein.
The results summarized above demonstrated that divergent transmembrane motifs can bind and activate the PDGF b receptor, suggesting that there are few absolute sequence requirements for this interaction. The inclusion of glutamine at position 17 and aspartic acid at position 33 in the library likely biased the interactions toward the PDGF b receptor and accounts for the ability of such a high percentage of the library proteins to transform cells. This result is consistent with biochemical studies which showed that insertion of hydrophilic residues into monomeric hydrophobic peptides induced them to homodimerize with high affinity by forming interhelical hydrogen bonds, but the strength of such hydrophilic interactions may facilitate the formation of nonspecific transmembrane complexes as well (Zhou et al., 2000; Gratkowski et al., 2001) .
In order to further explore the requirement for hydrophilic residues in the transmembrane domain for PDGF b receptor binding and activation, we constructed a second randomized library in which the glutamine at position 17 was not fixed. Rather, each randomized transmembrane segment contained, on average, between two and three hydrophilic amino acids evenly distributed throughout the sequence (FreemanCook et al., 2005) . Approximately 1% of the proteins from this library transformed fibroblasts, and the active proteins contained diverse transmembrane sequences (Figure 4 ). Like the library proteins identified in the first screen, the active proteins were dimeric, transformed cells by binding and activating the PDGF b receptor, and required receptor activity for signaling and transformation.
The transformation-competent proteins contained at most a single hydrophilic amino acid, and the position of this hydrophilic residue showed a strong bias. Approximately one-quarter of the transforming clones contained a hydrophilic residue at position 17, confirming the importance of a hydrophilic amino acid at the native position. Other hydrophilic residues were present adjacent to position 17 or at two other positions that lie in the E5 homodimer interface. These hydrophilic residues were essential for transforming activity. Strikingly, several of the transforming clones did not contain a hydrophilic residue in the randomized segment but still specifically activated the PDGF b receptor. This result indicates that hydrophobic packing interactions can be sufficient to induce specific PDGF b receptor dimerization and activation. Thus, productive interactions between small transmembrane proteins and a cellular target can occur in the absence of a hydrophilic interaction in the membrane-spanning segments.
Small transmembrane proteins that displayed different specificity than the E5 protein were also identified. The E5 protein cannot interact with a mutant PDGF b receptor containing leucine in place of the wild-type threonine at position 513 in the transmembrane domain, but several of the transforming proteins recovered from the library activated this mutant as well as other Note that the sequence at the bottom lacks hydrophilic amino acids Figure 5 Activation of the PDGF b receptor depends on specific transmembrane interactions. Luciferase expression driven by a PDGF receptor-responsive element was measured in response to expression of the E5 protein, v-sis (a form of PDGF), empty vector, and two proteins recovered from the library. Black bars, wild-type PDGF b receptor; gray bars, PDGF receptor containing a threonine to leucine substitution mutation in the transmembrane domain; white bars, chimeric PDGF receptor with a foreign transmembrane domain. Luciferase activity is expressed as the percentage of activity in cells coexpressing the E5 protein and the wild-type PDGF b receptor. Note that protein LFC2-T17 activates the mutant PDGF receptor, but the E5 protein and the LFC2-T1 protein do not activate this mutant. Only v-sis activates the chimeric receptor receptor transmembrane domain mutants that are not activated by the E5 protein (see LFC2-T17 in Figure 5) . However, the library proteins maintained significant specificity, since like the E5 protein, they did not activate a chimeric receptor containing the transmembrane domain of the PDGF a receptor, which shares 10 transmembrane amino acids with the PDGF b receptor. Taken together, these results demonstrated that it is possible to identify small transmembrane proteins that can bind and activate not only the wild-type PDGF b receptor but also mutant PDGF b receptors that are not activated by the E5 protein. More broadly, our results show that it is possible to select small transmembrane proteins able to form active hetero-oligomers in mammalian cells. Genetic schemes have been described that allow the selection of transmembrane domains capable of homodimerization in bacterial membranes (Russ and Engelman, 1999; Leeds et al., 2001) , but the development of biological selections for heterodimerizing transmembrane domains has been more difficult.
Potential uses of modular transmembrane proteins
On the basis of our results, we postulate that small transmembrane proteins can be identified or selected to bind to the transmembrane domains of a diverse array of viral and cellular proteins. Expression of these small transmembrane proteins may activate their targets or mediate the assembly of novel protein complexes. Importantly, it may also be possible to identify small transmembrane proteins that block the activity of their target proteins or disrupt naturally occurring multimeric protein complexes. Since intramolecular interactions between transmembrane helices are thought to mediate folding of proteins that cross the membrane multiple times, small transmembrane proteins that inhibit these interactions are likely to interfere with proper folding or membrane insertion. The development of this approach may generate new tools to influence the behavior of cells and open new avenues of drug discovery.
There are several examples in which dimerization or proper folding of transmembrane proteins is inhibited by expression or delivery of an isolated hydrophobic sequence derived from a natural transmembrane domain. Expression of the transmembrane domain of the ErbB2 receptor tyrosine kinase can interfere with the oligomerization of the activated receptor, inhibit ErbB2 activation, and inhibit the growth of ErbB2-transformed cells (Lofts et al., 1993; Bennasroune et al., 2004) . Several groups have blocked transmembrane protein function by using synthetic hydrophobic peptides that spontaneously insert into the cell membrane. This approach was used to inhibit G protein-coupled receptors, which contain seven transmembrane domains. Tarasova et al. (1999) demonstrated that synthetic peptides identical to individual transmembrane domains of CXCR4 and CCR5, two chemokine receptors required for the fusion of HIV to host cells, specifically blocked receptor signaling and HIV replication in vitro. The exogenous peptide was proposed to compete for the sites of interaction of the native transmembrane domains, disrupting receptor structure and activity. Hebert et al. (1996) demonstrated that a synthetic peptide derived from transmembrane domain VI of the b2-adrenergic receptor specifically inhibited receptor dimerization and ligand-induced receptor signaling, presumably by competing for binding to the dimerization interface. Similar approaches using small transmembrane peptides derived from other G proteincoupled receptors, the dopamine transporter, the T-cell antigen receptor, a sodium pump, and Escherichia coli diacylglycerol kinase and aspartate receptor have also been successful (Manolios et al., 1997; George et al., 1998 George et al., , 2003 Huynh et al., 2003; Partridge et al., 2003; Zouzoulas et al., 2003; Hernanz-Falcon et al., 2004; SalMan et al., 2004) . These experiments demonstrate the feasibility of inhibiting the function of a wide range of transmembrane proteins with naturally occurring transmembrane peptides.
The use of a genetic screen to select small artificial transmembrane proteins may provide significant advantages over using naturally occurring transmembrane domains. First, natural transmembrane domains can modulate the activity of only those proteins with which they normally interact. On the other hand, selecting for novel small transmembrane proteins would allow the targeting of potentially any transmembrane protein.
Although only a small fraction of transmembrane helices can homo-oligomerize with high affinity, it seems likely a priori that any transmembrane domain is able to participate in strong heteromeric interactions (even though a suitable hetero-oligomerization partner may not exist in nature). In addition, our identification of transmembrane domains that can bind to the PDGF b receptor with different specificity than the E5 protein and our discovery that hetero-dimerizing transmembrane helices do not necessarily require a strongly polar amino acid in the membrane-spanning segments suggest that many integral membrane proteins could serve as targets of this approach. Second, it is likely that a genetic selection can identify proteins that bind a particular transmembrane target with a higher affinity than does its natural partner, which may be under evolutionary constraints to limit affinity in order to maintain the ability to undergo conformational changes or to engage in alternative interactions. Such tight binders might have more potent effects on their target proteins. Finally, the discovery of small biologically active transmembrane proteins may be facilitated by their relatively high concentration in the two-dimensional plane of the membrane and by the propensity of membrane-spanning segments to associate lengthwise in well-defined simple helical structures such as right-and left-handed coiled-coils. In contrast, most short random protein segments that are not hydrophobic and constrained by the E5 scaffold are likely to be unstructured.
Several pieces of evidence indicate that the E5 dimer is a suitable scaffold for this approach. The E5 protein is comprised almost entirely of the membrane-spanning segment, so it is simple to engineer the protein and there are no extraneous soluble domains that might interfere with transmembrane recognition. It is well expressed, folds properly, and inserts into cellular membranes, even when it carries diverse hydrophobic sequences. Furthermore, a transmembrane dimer can present a larger potential interaction interface to its target than can a monomer. Manipulating the relatively large binding interface of a dimer may allow the generation of small transmembrane proteins that specifically recognize and bind a variety of cellular receptors or other transmembrane proteins. In addition to the E5 protein, it is possible that other natural or constructed small transmembrane proteins could serve as scaffolds for this approach. For example, although the E5 protein crosses the membrane in a type II orientation, libraries could also be constructed in a type I transmembrane backbone, such as the one used to express the transmembrane domain of ErbB2 (Bennasroune et al., 2004) .
In addition to cellular proteins, viral transmembrane proteins are potential targets. Many viruses encode transmembrane proteins that are required for a variety of functions including transit across the host cell membrane or assembly of essential transmembrane protein complexes such as the M2 ion channel of influenza virus (e.g. Takeda et al., 2002) . It may be possible to screen for small transmembrane proteins that can block virus replication by inhibiting the activity of these viral proteins. Furthermore, cellular transmembrane proteins are required for various aspects of the life cycle of many pathogens. For example, many viruses enter cells by binding to cell surface receptors. It may be possible to identify small transmembrane proteins that block these interactions and prevent viral entry or other steps in the viral life cycle.
Summary
The 44-amino-acid BPV E5 protein inserts into cellular membranes and binds to the transmembrane domain of the PDGF b receptor, resulting in receptor activation and cell transformation. The experiments summarized in this review suggest that it may be possible to construct and select similar small proteins that engage other cellular or viral transmembrane proteins. The identification of biologically active small transmembrane proteins is crucially dependent on the genetic selection utilized. Proteins that activated the PDGF b receptor were readily isolated because they induced the formation of transformed foci on a vast excess of normal cells. The selection of transmembrane proteins that inhibit protein function will pose a particular challenge. Nevertheless, if it is possible to design stringent selections for small transmembrane proteins that activate or inhibit various cellular or viral targets, this approach may represent an important new method to manipulate cellular function and treat or prevent disease.
